Enanta Pharmaceuticals, Inc.

240 articles with Enanta Pharmaceuticals, Inc.

• Enanta to Provide Updates on its R&D Programs and Business Outlook for 2020 during the 38th Annual J.P. Morgan Healthcare Conference

  1/9/2020

  Presentation and Q&A breakout to be webcast on January 13, 2020 beginning at 2:30 p.m. Pacific Time.

• Enanta Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

  12/30/2019

  Presentation and Question and Answer Session to be Webcast beginning at 2:30 p.m. PT on January 13, 2020

• Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

  11/21/2019

  Initiation of RSVP, a Phase 2b study of EDP-938 in adult outpatients with RSV

• Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019

  11/11/2019

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that three preclinical posters on EDP-305, Enanta’s lead Farnesoid X receptor (FXR) agonist, will be presented today at The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 8-12, 2019 in Boston.

• Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

  11/5/2019

  Enanta Pharmaceuticals, Inc., a clinical stage biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, announced that it plans to report its financial results for its fiscal fourth quarter and year ended September 30, 2019 after the U.S. markets close on November 21, 2019.

• Enanta Pharmaceuticals to Present at the 2019 Wolfe Research Healthcare Conference

  10/21/2019

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Wolfe Research Healthcare Conference on November 6 at 10:30 a.m. ET in New York City.

• New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions in Total Symptom Score, Mucus Weight and RSV Viral Load

  10/3/2019

  Enanta plans to initiate a Phase 2b clinical study of EDP-938 in adult out-patients with RSV by the end of 2019.

• New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions (p<0.001) in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay

  10/3/2019

  Enanta Pharmaceuticals, Inc. announced that new data from its Phase 2a Human Challenge Study of EDP-938 is being presented as a late-breaker oral presentation today at IDWeek™ 2019 in Washington, D.C. EDP-938 is Enanta’s lead N-protein inhibitor being developed for the treatment of RSV infection.

• Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH

  9/25/2019

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced topline results from its ARGON-1 Phase 2a study of EDP-305 for the treatment of non-alcoholic steatohepatitis (NASH).

• New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019

  9/10/2019

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new data from its Phase 2a Human Challenge Study of EDP-938 will be presented as a late-breaker oral presentation at IDWeek™ 2019, October 2-6, 2019 in Washington, D.C.

• Enanta Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference

  8/21/2019

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat presentation at the following investor conference:

• Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2019

  8/6/2019

  Cash and marketable securities totaled $389.2 million at June 30, 2019

• Enanta’s HCV Collaboration Partner AbbVie receives Approval by the European Commission for MAVIRET™ (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve HCV Patients with Compensated Cirrhosis

  8/2/2019

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the European Commission has granted marketing authorization to AbbVie for MAVIRET™ (glecaprevir/pibrentasvir) to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT)1, 2, 4, 5, or 6 infection

• Enanta Pharmaceuticals to Host Conference Call on August 6 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2019

  7/15/2019

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2019 after the U.S. markets close on August 6, 2019.

• Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-514, its Lead Core Inhibitor for the Treatment of Hepatitis B Virus (HBV)

  7/8/2019

  EDP-514 HBV Lead Asset Granted Fast Track Designation from FDA

• Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus (RSV)

  6/14/2019

  EDP-938 achieved highly statistically significant (p<0.001) reductions in viral load and in resolution of clinical symptoms compared to placebo

• Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences - June 10, 2019

  6/10/2019

  Enanta Pharmaceuticals, Inc. announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences

• Enanta Pharmaceuticals to Present at Upcoming Investor Conference

  5/14/2019

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat presentation format at the following investor conference:

• Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2019

  5/7/2019

  Data from Phase 2a RSV program anticipated mid-2019 and Phase 2a NASH program by the end of third quarter of calendar 2019

• Enanta Pharmaceuticals to Host Conference Call on May 7th at 4:30 pm ET to Discuss Its Financial Results for Its Fiscal Second Quarter Ended March 31, 2019

  4/22/2019

  Enanta Pharmaceuticals, Inc. announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2019 after the U.S. markets close on May 7, 2019.